GlassScriptPhysician profile
Stephen K Rogers
NPI 1609879675
$3,559.12
in general payments reported to CMS, 2019-2025
28 companies · $1,434 in 2025
The $1,434 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $492 · 2023: $813 · 2024: $820 · 2025: $1,434.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,067.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,066.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $927.65 | 2022-2025 | |
| Abbvie INC. | $819.17 | 2022-2025 | Vraylar, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $448.13 | 2023-2025 | Breztri, Airsupra, Farxiga |
| Otsuka America Pharmaceutical, INC. | $233.98 | 2022-2025 | Rexulti |
| Braeburn INC. | $163.97 | 2025 | Brixadi |
| Amgen INC. | $102.78 | 2023-2025 | Otezla, Repatha, Otezla |
| Mallinckrodt Hospital Products INC. | $93.70 | 2024-2025 | Acthar |
| Novo Nordisk INC | $84.54 | 2022-2025 | Ozempic, Rybelsus |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $82.19 | 2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $79.91 | 2025 | Fanapt |
| Novartis Pharmaceuticals Corporation | $79.31 | 2022-2023 | |
| Lilly USA, LLC | $68.31 | 2022-2024 | Zepbound, Mounjaro, Jardiance |
| Alkermes, INC. | $65.80 | 2022-2023 | Vivitrol |
| Aimmune Therapeutics, INC. | $36.25 | 2025 | Vowst, Zenpep |
| Tris Pharma INC | $30.92 | 2025 | Dyanavel Xr |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $27.68 | 2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $25.19 | 2025 | Spravato |
| Phathom Pharmaceuticals, INC. | $24.16 | 2024 | Voquezna |
| Electromed, INC. | $20.76 | 2025 | Smartvest |
| Indivior INC. | $19.60 | 2025 | Sublocade |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.49 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $17.87 | 2022 | |
| Abbott Laboratories | $15.63 | 2024 | Freestyle Libre 3 |
| Collegium Pharmaceutical, INC. | $14.88 | 2022 | |
| Braintree Laboratories, INC. | $14.87 | 2025 | Sutab, Suflave |
| Exact Sciences Corporation | $14.83 | 2025 | Cologuard Collection Kit |
| Supernus Pharmaceuticals, INC. | $14.13 | 2025 | Qelbree |
| Dexcom, INC. | $13.42 | 2023 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Rogers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.